For non-Sq NSCLC, we found that the favorable factors for PFS were platinum plus pemetrexed, BHMT polymorphisms (Fig. 3b), a high FA level before premedication, bevacizumab combination, DHFR polymorphisms (Fig. 3c), and a low B12 level before pemetrexed treatment (Fig. 5a) and that favorable prognostic factors were good ECOG-PS, a high BMI, a high FA level before premedication, high RBP level before pemetrexed treatment, MTRR polymorphisms (Fig. 4b), and low SI (Fig. 5b). Here, DHFR is linked to non-small cell lung carcinoma.